Reset Map6 Results
Unit 6, 138 Juliette Street Greenslopes,QLD 4120 AustraliaTBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
2806 ipswich Rd., Darra Queensland 4076, AustraliaTBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
Level 18, 101 Collins St., Melbourne VIC, 3000 AustraliaTBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
13F., No.237, Sec. 1, Datong Rd, Xizhi Dist., New Taipei City, 221 TaiwanTBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
4F-1, Building No.3, No.2004 West Wengjiao Rd., Haicang Dist., Xiamen City, 361027, ChinaTBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
635 Presidential Dr,, Richardson, TX 75081 USATBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnotics kits, instruments and services. Company Structure Picture TDL is comprised of the following subsidiaries: Texas BioGene Inc. in USA, TBG Biotechnology Corp. in Taiwan, and TBG Biotechnology Inc. (Xiamen) in China. Each subsidiary is focused on different business or functions. Texas Biogene Inc. is the research center, TBG Biotechnology Corp. Taiwan, is focused on Transplant and Transfusion Genetics, and TBG Biotechnology (Xiamen) Inc. is focused on Infectious Disease, and Oncology. History Texas BioGene Inc (TBG) was founded in Texas, USA (1999), TBG is one of the leading providers of quality Human Leukocyte Antigen (HLA) Typing Kits for immune matching of bone marrow, cord blood and organ transplants. TBG has instituted a comprehensive quality control system and is an ISO13485 accredited manufacturer of medical devices including CE approved typing kits. Currently TBG has R&D, manufacturing and sales operations in the US, Taiwan and China. In 2006, Medigen Biotechnology Corp. acquired TBG for its potential in PCR diagnostics and to complement its existing drug development pipelines. To take advantage of the rapid growth in IVD market within China, Medigen Biotechnology Corp. acquired Shanghai Haoyuan in 2007 for its diagnostic distribution channels and licenses in China. By combining the strengths in TBG and Haoyuan, a new generation of Blood Screening was developed and succesfully marketed in China. In 2012, Perkin Elmer decided to acquired Shanghai Haoyuan from Medigen Biotechnology Corp. as a way to enter the Blood Screening business in China. While China is still a rapidlly growing market for IVD, TBG re-established the TBG Biotechnoloyg Inc. (Xiamen) as its new China subsidiary. The intent of this China facility is to go beyond the current scope of products and to become a major IVD leader in China. In early 2016, Progen Pharmaceiticals has decided to acquire TBG I. and rename the company to TBG Diagnostics Limited (TDL).
Site Information
The Contract Research Map is owned and maintained by Scientist.com. It was created to help researchers in the life sciences identify and connect with contract research organizations (CROs) based on geography. Updated nightly, this map features all of the available CROs within our network, so you can order services with a few clicks. Click on a specific country, scroll on the map itself or type into the search bar at the top—there are many ways to find the location and suppliers that you’re looking for. From Argentina to New Zealand, use this map to connect with a CRO near you.
We believe that every researcher across the world should be able to connect with the thousands of global CROs that exist and have the opportunity to work together. Like many industries,the life science supply chain has been disrupted over the last year. But there are many other circumstances such as international customs regulations or sensitive shipping times that create limitations around which countries are feasible to partner with. Sometimes, finding a CRO based in a country that best suits your research needs is imperative. We hope this contract research map allows you to find the right partner in the right place at the right time.
Have questions or feedback? We’d love to help. You can find our FAQs and contact information on the Learn more page.
Interested in connecting with one or more of the contract research organizations listed on this map? By clicking on the company’s name, you will be directed to their supplier profile on the Scientist.com marketplace. Once you set up a marketplace account you can start the ordering process immediately.
What is Scientist.com?
Scientist.com is the world's largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies.
How can I use Scientist.com?
Scientist.com has built private, enterprise marketplaces from 24 of the 30 largest pharmaceutical companies, 80+ biotech companies, the US National Institutes of Health (NIH) and numerous other pharma and biotech companies. If you are employed by one of these organizations, you can log in to get started today. If you are unsure about how to get started, you can email our team at support@scientist.com or go to our website www.scientist.comto speak to someone via our live chat.
Why should I place my order through Scientist.com?
Scientist.com is a highly efficient enterprise-wide outsourcing marketplace that makes it possible for research organizations to save time and money, access innovation and ensure compliance. It utilizes a universal legal agreement and AI technologies to enable research like never before. See how comparing proposals and getting 1-on-1 support from our Research Concierge® team will enable you to place more research today.
How do I get my organization listed on the map?
If your CRO isn’t showing up on the map, then please be sure your company profile is up to date in Scientist.com’s Backoffice. After logging in, click the Your Company button in the navigation at the top, and then select the Locations tab.
Information about my organization is incorrect, how do I fix it?
Head over to backoffice.scientist.com to update your supplier profile and information. It may take up to two business days for the updates to be reflected on the map.